众生药业：来瑞特韦片、昂拉地韦片已获批上市，昂拉地韦颗粒及片剂儿童青少年III期临床试验完成入组

Group 1 - The company has two innovative drugs, Lai Ruitewei tablets and Angladiwei tablets, that have been approved for market launch [1] - Angladiwei tablets have been included in the 2025 version of the National Medical Insurance Catalog [1] - The Phase III clinical trials for Angladiwei granules for treating uncomplicated influenza A in children aged 2 to 11 and Angladiwei tablets for treating uncomplicated influenza A in adolescents aged 12 to 17 have successfully completed participant enrollment [1]